Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 13/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103226 | 1.00 | CYP19A1 (0.53) | CYP19A1ESR2ESR1LMNATSHR | |
| SCHEMBL13261222 | 1.00 | CYP19A1 (0.53) | CYP19A1ESR2ESR1LMNATSHR | |
| SCHEMBL13979324 | 0.98 | CYP19A1 (0.51) | CYP19A1ESR2ESR1LMNATSHR | |
| SCHEMBL11800559 | 0.89 | CYP19A1 (0.46) | CYP19A1ESR2ESR1LMNATSHR | |
| SCHEMBL10078998 | 0.87 | — | — | |
| SCHEMBL15307858 | 0.87 | — | — | |
| SCHEMBL29946338 | 0.77 | LMNA (0.36) | CYP19A1LMNATSHR | |
| SCHEMBL10577146 | 0.76 | CYP19A1 (0.43) | CYP19A1ESR2ESR1LMNATSHR | |
| SCHEMBL3857564 | 0.75 | CYP19A1 (0.49) | CYP19A1 | |
| SCHEMBL18994259 | 0.74 | CYP19A1 (0.52) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058977-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058977-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | FNTB, DCXR, TREH | CYP19A1 4297/4885ESR2 4401/4885ESR1 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.